Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Leases (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Current Leases for 6 consecutive years, with $2.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Current Leases rose 2.67% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Mar 2025, up 2.67%, and an annual FY2023 reading of $1.8 million, up 312.24% over the prior year.
  • Current Leases was $2.0 million for Q1 2025 at Barinthus Biotherapeutics, up from $1.9 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.0 million in Q1 2025 and bottomed at $186000.0 in Q3 2022.
  • Average Current Leases over 5 years is $824714.3, with a median of $479000.0 recorded in 2021.
  • The sharpest move saw Current Leases crashed 57.24% in 2022, then skyrocketed 706.99% in 2023.
  • Year by year, Current Leases stood at $523000.0 in 2021, then dropped by 17.21% to $433000.0 in 2022, then skyrocketed by 312.24% to $1.8 million in 2023, then grew by 6.95% to $1.9 million in 2024, then increased by 2.67% to $2.0 million in 2025.
  • Business Quant data shows Current Leases for BRNS at $2.0 million in Q1 2025, $1.9 million in Q1 2024, and $1.8 million in Q4 2023.